Pfizer’s Lyrica: DEA Proposes Schedule V Designation, Comments Due June 13
This article was originally published in The Pink Sheet Daily
Executive Summary
The pregabalin launch is at least a month away following the Drug Enforcement Administration’s proposed rule on controlled substance scheduling for the neuropathic pain agent. Lyrica has a “low potential for abuse” relative to Schedule IV substances, DEA says.
You may also be interested in...
Lyrica Controlled Substance Scheduling Finalized By DEA
Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.
Lyrica Controlled Substance Scheduling Finalized By DEA
Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.
Lyrica Will Be Available In Fall, Pfizer Says
Pfizer announces approval of the third indication for Lyrica (pregabalin) on the same day that comments are due on the Drug Enforcement Agency’s proposed scheduling for the product. The Neurontin follow-on will launch with three out of four original indications.